Report of the 2014 Cent Gardes HIV Vaccine Conference-Part 2: Cell-mediated immunity, mucosal protection, and clinical trials. Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October, 2014

The 2014 Cent Gardes Conference took place on October 5-7, 2014, at the Fondation Mérieux Confer-ence Center, on the shores of the Annecy Lake and aimed to review the progress and promise of HIVvaccines. The elicitation of broadly neutralizing antibodies (bNAbs), their use in passive immunization,as well as their genetic delivery (vector immunoprophylaxis) by a recombinant Adenovirus-associatedvirus (AAV) vector were reviewed in a preceding article [1]. Approaches to the elicitation of long-lastingT cell or mucosal immunity were also discussed and are now reviewed here. The possibility of elici-ting mucosal IgAs was discussed, since it was demonstrated that transcytosis-blocking IgAs can protectmonkeys against repeated vaginal challenge with a pathogenic chimeric simian and human immuno-deficiency virus (SHIV). The possibility of purging the HIV reservoirs from HIV-infected persons anddeveloping a cure of the disease was also discussed.